Tuglif-M
BRAND NAME:
Tuglif-M
GENERIC NAME:
Ertugliflozin + Metformin HCl
THERAPEUTIC SEGMENT:
Antidiabetic
INDICATIONS:
Tuglif-M is a combination of ertugliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
BRIEF DESCRIPTION:
Ertugliflozin + Metformin is an orally bioavailable, fixed-dose combination therapy for the management of type 2 diabetes mellitus (T2DM). Ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, lowers blood glucose levels by reducing renal glucose reabsorption, promoting glycosuria, and contributing to weight loss and blood pressure reduction. Metformin, a biguanide, decreases hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake. Together, these agents provide a complementary mechanism of action to achieve better glycemic control while also offering potential cardiovascular and renal benefits.
DOSAGE FORM:
Tablets
2.5mg+1000mg
7.5mg+1000mg
Disclaimer: For use under medical prescription only
Reviews
There are no reviews yet.